Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Connect Biopharma Posts Q2 Revenue Drop

TheMotleyFool 
0 0 13.08.25
Connect Biopharma Posts Q2 Revenue Drop
 

Connect Biopharma (NASDAQ:CNTB), a biotechnology company developing therapies for inflammatory diseases, released its second quarter 2025 earnings on August 13, 2025. The main highlight was a substantial drop in GAAP revenue, from $24.1 million in Q2 2024 to just $48,000 in Q2 2025. Reported GAAP earnings per share (EPS) were $(0.23) for Q2 2025. Research and development spending (GAAP) increased sharply, reflecting new and ongoing clinical trials, while cash reserves declined but remained adequate.

Source: Analyst estimates for the quarter provided by FactSet.

Connect Biopharma works to develop new therapies targeting immune and inflammatory diseases. Its primary focus is on rademikibart, a monoclonal antibody product designed to treat asthma and chronic obstructive pulmonary disease (COPD). The company is in a pre-commercial phase, meaning it does not yet sell products and relies on licensing revenue and existing cash to fund research and development. Most of its near-term success hinges on progressing clinical trials and achieving regulatory approvals for rademikibart and other pipeline candidates.

Continue reading


Source Fool.com

Electro Power Systems S.A. Stock

Show more
Like: 0
CNTB
Share

Comments

Not a member yet? Sign up for free!